Hydralyte
| Role | Organisation | Sources |
|---|---|---|
| North American General Manager (former) | Swisse | BW Equities (Tue 14 Dec 2021), BW Equities (Mon 22 Nov 2021), BW Equities (Wed 20 Oct 2021) |
| Hydralyte | BW Equities (Mon 22 Nov 2021), BW Equities (Wed 20 Oct 2021) |
Stories naming Oliver Baker. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Hydration Pharmaceuticals, which sells Hydralyte in North America, listed on the ASX, raising $17 million at 29 cents and closing 22.4% higher. Former Swisse executives hold key roles and large stakes.
Hydralyte's North American arm, run by former Swisse executives, has begun an institutional roadshow for a $17 million ASX listing planned for December, with BW Equities handling the raising.
Also BW Equities